구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Kadcyla, T-DM1 (Control drug: Trastuzumab emtansine, Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)) Shanghai Fosun Pharmaceutical Indu…·Breast Cancer 84 trials |
|---|---|
Overview Program | Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) |
Overview Company | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. |
Overview Modality | ADC |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | DM1 via butelase-1 with ABD fusion for pote |
Technology Linker | cleavable linkers, and novel payloads, such as topoisome |
MoA Mechanism | targeting human epidermal growth factor receptor |
MoA Biomarker | HER2-positive |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | tumor growth inhibition |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | thrombocytopenia |
Clinical Safety signal | thrombocytopenia |
Clinical Selected reported efficacy | ORR 79.7% |
Clinical Reported ORR | 77.0% |
Clinical Reported PFS | NA |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03529110 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT03529110 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Kadcyla, T-DM1 (Control drug: Trastuzumab emtansine, Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)) Shanghai Fosun Pharmaceutical Indu…·Breast Cancer 84 trials |
|---|---|
Overview Program | Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) |
Overview Company | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. |
Overview Modality | ADC |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer |
Overview Phase | PHASE_3 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | DM1 via butelase-1 with ABD fusion for pote |
Technology Linker | cleavable linkers, and novel payloads, such as topoisome |
MoA Mechanism | targeting human epidermal growth factor receptor |
MoA Biomarker | HER2-positive |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | tumor growth inhibition |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | thrombocytopenia |
Clinical Safety signal | thrombocytopenia |
Clinical Selected reported efficacy | ORR 79.7% |
Clinical Reported ORR | 77.0% |
Clinical Reported PFS | NA |
Clinical Reported OS | NA |
Clinical Result source | ClinicalTrials.gov NCT03529110 |
Clinical Program phase | PHASE_3 |
Clinical Trial ref | NCT03529110 |
추천 비교
추천 비교